Three-dimensional stability of Burgers vortices

Burgers vortices are explicit stationary solutions of the Navier-Stokes equations which are often used to describe the vortex tubes observed in numerical simulations of three-dimensional turbulence. In this model, the velocity field is a two-dimensional perturbation of a linear straining flow with axial symmetry. The only free parameter is the Reynolds number $Re = \Gamma/\nu$, where $\Gamma$ is the total circulation of the vortex and $\nu$ is the kinematic viscosity. The purpose of this paper is to show that Burgers vortex is asymptotically stable with respect to general three-dimensional perturbations, for all values of the Reynolds number. This definitive result subsumes earlier studies by various authors, which were either restricted to small Reynolds numbers or to two-dimensional perturbations. Our proof relies on the crucial observation that the linearized operator at Burgers vortex has a simple and very specific dependence upon the axial variable. This allows to reduce the full linearized equations to a vectorial two-dimensional problem, which can be treated using an extension of the techniques developped in earlier works. Although Burgers vortices are found to be stable for all Reynolds numbers, the proof indicates that perturbations may undergo an important transient amplification if $Re$ is large, a phenomenon that was indeed observed in numerical simulations.Comment: 31 pages, no figur

Small Hydrophobic Protein of Human Metapneumovirus Does Not Affect Virus Replication and Host Gene Expression In Vitro

Human metapneumovirus (HMPV) encodes a small hydrophobic (SH) protein of unknown function. HMPV from which the SH open reading frame was deleted (HMPVΔSH) was viable and displayed similar replication kinetics, cytopathic effect and plaque size compared with wild type HMPV in several cell-lines. In addition, no differences were observed in infection efficiency or cell-to-cell spreading in human primary bronchial epithelial cells (HPBEC) cultured at an air-liquid interphase. Host gene expression was analyzed in A549 cells infected with HMPV or HMPVΔSH using microarrays and mass spectrometry (MS) based techniques at multiple time points post infection. Only minor differences were observed in mRNA or protein expression levels. A possible function of HMPV SH as apoptosis blocker, as proposed for several members of the family Paramyxoviridae, was rejected based on this analysis. So far, a clear phenotype of HMPV SH deletion mutants in vitro at the virus and host levels is absent

Using a reference when defining an abnormal MRI reduces false-positive MRI results-a longitudinal study in two cohorts at risk for rheumatoid arthritis

Pathophysiology and treatment of rheumatic disease

EVALUATION OF THE ACCURACY OF HAND AND FOOT MRI IN THE EARLY IDENTIFICATION OF RA: USING THE PREVALENCE OF LOW-GRADED INFLAMMATION IN THE SYMPTOM-FREE POPULATION AS REFERENCE REDUCES FALSE-POSITIVE MRI RESULTS

Pathophysiology and treatment of rheumatic disease

Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial.

PURPOSE: Pemetrexed is a chemotherapeutic drug in the treatment of non-small cell lung cancer and mesothelioma. Optimized dosing of pemetrexed based on renal function instead of body surface area (BSA) is hypothesized to reduce pharmacokinetic variability in systemic exposure and could therefore improve treatment outcomes. The aim of this study is to compare optimized dosing to standard BSA-based dosing. METHODS: A multicenter randomized (1:1) controlled trial was performed to assess superiority of optimized dosing versus BSA-based dosing in patients who were eligible for pemetrexed-based chemotherapy. The individual exposure to pemetrexed in terms of area under the concentration-time curve (AUC) was determined. The fraction of patients attaining to a predefined typical target AUC (164 mg × h/L ± 25%) was calculated. RESULTS: A total of 81 patients were included. Target attainment was not statistically significant different between both arms (89% vs. 84% (p = 0.505)). The AUC of pemetrexed was similar between the optimized dosing arm (n = 37) and the standard of care arm (n = 44) (155 mg × h/L vs 160 mg × h/L (p = 0.436). CONCLUSION: We could not show superiority of optimized dosing of pemetrexed in patients with an adequate renal function does not show added value on the attainment of a pharmacokinetic endpoint, safety, nor QoL compared to standard of care dosing. CLINICAL TRIAL NUMBER: Clinicaltrials.gov identifier: NCT03655821